PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).

Adult Child Humans Severity of Illness Index Immunosuppressive Agents / therapeutic use Prednisolone Consensus Lupus Erythematosus, Systemic / diagnosis
Childhood-SLE Low disease activity T2T Treat-to-target cLLDAS cSLE

Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
05 2023
Historique:
received: 10 01 2023
revised: 14 03 2023
accepted: 15 03 2023
pmc-release: 01 05 2024
medline: 28 4 2023
pubmed: 20 3 2023
entrez: 19 3 2023
Statut: ppublish

Résumé

To achieve a consensus-based definition of Low Disease Activity (LDA) for use in cSLE trials. The International cSLE T2T Task Force, comprising of paediatric rheumatologists/nephrologists, and adult rheumatologists undertook a series of Delphi surveys/consensus meetings to discuss, refine, and vote upon cSLE LDA criteria. The Task Force agreed that LDA should be based upon the adult-SLE Lupus Low Disease Activity State definition (LLDAS), with modifications to make it applicable to cSLE (cLLDAS). They agreed upon five cLLDAS criteria: (1) SLE Disease Activity Index (SLEDAI)-2 K ≤4, with no activity in major organ systems; (2) no new features of lupus disease activity compared with the last assessment; (3) Physician Global Assessment score of ≤1 (0-3 scale); (4) prednisolone dose of ≤0.15 mg/kg/day, 7.5 mg/day/maximum; while on (5) stable antimalarials, immunosuppressives, and biologics. A cSLE-appropriate definition of cLLDAS has been generated, maintaining alignment with the adult-SLE definition to promote life-course research.

Identifiants

DOI: 10.1016/j.clim.2023.109296 PMID: 36934849 PMC: PMC10500564
pubmed: 36934849
pii: S1521-6616(23)00075-X
doi: 10.1016/j.clim.2023.109296
pmc: PMC10500564
mid: NIHMS1927121
pii:
doi:

Substances chimiques

Immunosuppressive Agents 0
Prednisolone 9PHQ9Y1OLM

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109296

Subventions

Organisme : Versus Arthritis
ID : ARUK-20621
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : ZIA AR041214
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 AR999999
Pays : United States
Organisme : Wellcome Trust
ID : 204822Z16Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Investigateurs

B Goilav (B)
S Marks (S)
L Oni (L)

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests in relation to this manuscript.

Références

Ann Rheum Dis. 2017 Dec;76(12):2071-2074
pubmed: 28939626
Rheumatology (Oxford). 2021 Dec 1;60(12):5630-5641
pubmed: 33629109
Arthritis Rheumatol. 2019 Jul;71(7):1163-1173
pubmed: 30848528
Ann Rheum Dis. 2014 Jun;73(6):958-67
pubmed: 24739325
Arthritis Rheum. 2009 Jan 15;61(1):13-20
pubmed: 19116979
Lupus. 2021 Nov;30(13):2144-2150
pubmed: 34723709
Ann Rheum Dis. 2017 Mar;76(3):554-561
pubmed: 27884822
Arthritis Care Res (Hoboken). 2017 Jul;69(7):997-1003
pubmed: 27696791
Lupus Sci Med. 2018 Feb 27;5(1):e000234
pubmed: 29531772
Ann Rheum Dis. 2019 Jan;78(1):51-59
pubmed: 30309970
Lupus Sci Med. 2021 Nov;8(1):
pubmed: 34819388
Rheumatology (Oxford). 2017 Jan;56(1):121-128
pubmed: 27803306
Ann Rheum Dis. 2023 Jun;82(6):788-798
pubmed: 36627168
Lancet. 1997 Jul;350 Suppl 1:SI29-32
pubmed: 9250281
Ann Rheum Dis. 2018 Jan;77(1):104-110
pubmed: 28970217
Arthritis Rheumatol. 2018 Nov;70(11):1790-1795
pubmed: 29806142
Nat Rev Rheumatol. 2022 Mar;18(3):146-157
pubmed: 35039665
Rheumatology (Oxford). 2022 Aug 3;61(8):3378-3389
pubmed: 34894234
Arthritis Rheum. 2008 Feb;58(2):556-62
pubmed: 18240232
Rheumatology (Oxford). 2020 Dec 1;59(12):3622-3632
pubmed: 32789462
Semin Arthritis Rheum. 2019 Oct;49(2):267-272
pubmed: 31235075
Arthritis Rheum. 2006 Aug;54(8):2550-7
pubmed: 16868977
Rheum Dis Clin North Am. 2010 Feb;36(1):53-80, vii-viii
pubmed: 20202591
J Rheumatol. 2009 Mar;36(3):560-4
pubmed: 19208608
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
BMC Rheumatol. 2022 Oct 15;6(1):69
pubmed: 36242078
Lupus. 2016 Dec;25(14):1542-1550
pubmed: 27147622
Lancet. 1994 Aug 6;344(8919):380-5
pubmed: 7914311
Lancet. 2004 Jul 17-23;364(9430):263-9
pubmed: 15262104
Indian J Endocrinol Metab. 2014 Mar;18(2):166-74
pubmed: 24741511
Lupus Sci Med. 2021 Dec;8(1):
pubmed: 34969874
Semin Arthritis Rheum. 2018 Dec;48(3):467-474
pubmed: 29555348
Arthritis Res Ther. 2017 Nov 10;19(1):247
pubmed: 29126432
Lancet. 2015 Dec 19;386(10012):2489-98
pubmed: 26433318
Arthritis Care Res (Hoboken). 2020 Sep;72(9):1289-1295
pubmed: 31282076
Lupus. 2008 Apr;17(4):314-22
pubmed: 18413413
RMD Open. 2019 May 23;5(1):e000955
pubmed: 31245057
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Korean Circ J. 2019 Nov;49(11):1002-1009
pubmed: 31646769

Auteurs

E M D Smith (EMD)

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. Electronic address: esmith8@liverpool.ac.uk.

A Aggarwal (A)

Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

J Ainsworth (J)

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

E Al-Abadi (E)

Department of Paediatric Rheumatology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.

T Avcin (T)

Department of Allergology, Rheumatology and Clinical Immunology, Children's Hospital, University Medical Center Ljubljana, Slovenia.

L Bortey (L)

TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

J Burnham (J)

Department of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, USA.

C Ciurtin (C)

Centre for Adolescent Rheumatology Versus Arthritis, Division of Medicine, University College London, UK.

C M Hedrich (CM)

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

S Kamphuis (S)

Department of Pediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands.

L Lambert (L)

TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

D M Levy (DM)

Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Canada.

L Lewandowski (L)

Lupus Genomics and Global Health Disparities Unit, Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

N Maxwell (N)

TARGET Lupus Public Patient Involvement and Engagement Group, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.

E Morand (E)

Centre for Inflammatory Diseases, Monash University, Melbourne, Australia.

S Ozen (S)

Department of Pediatrics, Hacettepe University, Ankara, Turkey.

C E Pain (CE)

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

A Ravelli (A)

Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy; Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno Infantili (DINOGMI), Università degli Studi di Genova, Genoa, Italy.

C Saad Magalhaes (C)

Department of Pediatric Rheumatology, Botucatu Medical School, Sao Paulo State University, Sao Paulo, Brazil.

C Pilkington (C)

Department of Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

D Schonenberg-Meinema (D)

Department of Pediatric Immunology, Rheumatology and Infectious diseases, Emma Children's Hospital, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands.

C Scott (C)

Clinical Research Centre, Department of Pediatric Rheumatology, University of Cape Town, Cape Town, South Africa.

K Tullus (K)

Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

M W Beresford (MW)

Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes de santé › Indicateurs d'état de santé › Acuité des besoins du patient › Indice de gravité de la maladie › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunosuppresseurs › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Prégnanes › Prégnadiènes › Prégnadiènetriols › Prednisolone › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › PReS-endorsed international childhood lupus...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › PReS-endorsed international childhood lupus...